SOUČASNÉ MOŽNOSTI POUŽITÍ IVOSIDENIBU V TERAPII AKUTNÍ MYELOIDNÍ LEUKÉMIE

Ivosidenib v terapii akutní myeloidní leukémie

Abstract

Acute myeloid leukemia is the most common type of acute leukemia in adults. The long-term results of therapy remain unsatisfactory for the majority of patients. Ongoing research into the process of malignant transformation of the hematopoietic stem cells has revealed new mutations that represent attractive targets for modern drugs. Ivosidenib, an inhibitor of mutated isocitrate dehydrogenase 1 (IDH1), has shown encouraging results in combination with azacitidine in patients with previously untreated acute myeloid leukemia with an IDH1 mutation. The review discusses the current possibilities of using ivosidenib in patients with acute myeloid leukemia in the Czech Republic.